Description:
Current
State of the Art:
Disruption of the endothelial barrier occurs during inflammatory
diseases such as acute lung injury and acute respiratory distress syndrome with
an overall mortality rate of 30-40% and results in the movement of fluid and
macromolecules into the interstitium and pulmonary air spaces causing pulmonary
edema.
Disadvantages
of the Current Art:
In spite of intense research, there is still no successful
pharmacologic treatment strategy for lung diseases involving pulmonary
endothelial cell barrier breakdown although surfactant, inhaled nitric oxide,
corticosteroids, antifungal drugs, and phosphodiesterase inhibitors have been
used unsuccessfully.
Advantages
of the Invention:
β-NAD improves the mortality of acute
lung injury and acute respiratory distress syndrome by protecting against endothelial
cell barrier dysfunction.
Patent
Status: PCT
Filed
Inventors:
Umpathy
Siddaramappa, Ph.D; Alexander Verin, Ph.D; Joyce Gonzales,
Ph.D
Case
Number: GHSU
2010-030